Former Gilead R & D chief to lead cancer drug startup in Cambridge

One month after stepping down as head of research and development at Gilead Sciences, Norbert Bischofberger has taken the helm of a new cancer drug startup in Cambridge. Kronos Bio formally announced its launch on Wednesday. The company is operating out of LabCentral, and has collected $18 million in seed financing from various venture funds and individual investors. They include Bischofberger, who spent more than 30 years with California-based Gilead (Nasdaq: GIL D) before leaving in April. Kronos’…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news